Immunisation with DNA encoding Leishmania infantum protein papLe22 decreases the frequency of parasitemic episodes in infected hamsters.
We tested in outbred golden hamsters the protective potential of highly immunogenic Leishmania infantum protein papLe22 which we recently identified. Immunisation was performed using papLe22 cDNA, administered as a single intramuscular injection. The level of antibodies directed against total leishmanial antigens was significantly decreased in the vaccinated hamsters as compared with the controls, indicating that the administration of papLe22 cDNA downregulated the Th2 type response and suggesting that the immune response was reoriented toward the cell-mediated type. The presence of the parasite kDNA in the peripheral blood was systematically detected as early as 3 weeks post infection in all mock-vaccinated hamsters. By contrast, in the vaccinated animals the occurrence of the episodes of Leishmania circulation was reduced by 50%. The immunisation presenting efficacy in this highly susceptible species which develop VL similar in gravity to human and canine disease should prove also efficient in naturally infected hosts. The marked decrease of the frequency of parasite circulation induced by papLe22 cDNA immunisation appears therefore important and potentially able to reduce transmission and thus to control the spread of the disease.
Fragaki
K
K
Groupe de Recherche en Immunopathologie de la Leishmaniose (EA 2675), Laboratoire de Parasitologie, IFR 50, Faculté de Médecine, Avenue de Valombrose, 06107 Cedex 2, Nice, France.
Suffia
I
I
Ferrua
B
B
Rousseau
D
D
Le Fichoux
Y
Y
Kubar
J
J
D000818:Animals; D000913:Antibodies, Protozoan / Q000276:immunology; D000953:Antigens, Protozoan / Q000235:genetics / Q000276:immunology*; D002460:Cell Line; D006224:Cricetinae; D018105:DNA, Kinetoplast / Q000097:blood / Q000235:genetics; D004285:Dogs; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D018314:Leishmania infantum / Q000187:drug effects / Q000235:genetics / Q000276:immunology* / Q000502:physiology; D007898:Leishmaniasis, Visceral / Q000188:drug therapy / Q000276:immunology* / Q000469:parasitology / Q000662:veterinary; D008647:Mesocricetus / Q000097:blood / Q000276:immunology* / Q000469:parasitology*; D051379:Mice; D018512:Parasitemia / Q000097:blood / Q000188:drug therapy / Q000276:immunology* / Q000469:parasitology; D016052:Protozoan Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D018418:Th2 Cells / Q000276:immunology; D014611:Vaccination; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*
D000913:Antibodies, Protozoan; D000953:Antigens, Protozoan; D018105:DNA, Kinetoplast; D016052:Protozoan Vaccines; D019444:Vaccines, DNA